234 CHAPTER 3.2 Table 3. Most commonly identified STOPP/START recommendations and implementation at 2 months. STOPP/ START Description Count in intervention group, N (%) Implemented, N (%) Not imple- mented, N (%) STOPP STOPP A1 1 Any drug prescribed without an evidence-based clinical indication 828 (35.5) 428 (51.7) 400 (48.3) STOPP A3 Any duplicate drug class prescription 147 (6.3) 95 (64.6) 52 (35.4) STOPP D5 Benzodiazepines for ≥ 4 weeks 115 (4.9) 45 (39.1) 70 (60.9) START START E3 Vitamin D supplement in patients with known osteoporosis and previous fragility fracture(s) and/or Bone Mineral Density T-scores more than -2.0 in multiple sites 96 (4.1) 22 (22.9) 74 (77.1) START H2 Laxatives in patients receiving opioids regularly 82 (3.5) 12 (14.6) 70 (85.4) START A6 Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery disease 80 (3.4) 19 (23.8) 61 (76.3) START E5 Vitamin D supplement in older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is > -1.0 but < -2.5 in multiple sites) 80 (3.4) 31 (38.8) 49 (61.3) START E2 Bisphosphonates and vitamin D and calcium in patients taking long-term systemic corticosteroid therapy 74 (3.2) 21 (28.4) 53 (71.6) START E4 Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, denosumab) in patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores -> 2.5 in multiple sites) and/or previous history of fragility fracture(s) 71 (3.0) 9 (12.7) 62 (87.3)
RkJQdWJsaXNoZXIy MTk4NDMw